Antimicrobial Peptides and Antimicrobial Nanomaterials in Biomedicine
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 2988
Special Issue Editor
Interests: bioengineering; nanotechnology; medical biotechnology; biomaterials; biological sciences; microbiology; antimicrobial drugs; non-antibiotic therapeutics; treatment of bacterial infections; gastric infection; gut microbiome
Special Issue Information
Dear Colleagues,
The development of antibiotics is one of the greatest medical achievements of the 20th Century, saving countless lives. However, as the use of these drugs increased, so did bacterial resistance. Antibiotic resistance is growing faster than it was expected to, being considered a main public health challenge and one of the biggest threats to global health and development.
Using antimicrobial peptides (AMPs) and antimicrobial nanomaterials is an excellent strategy to overcome this problem.
AMPs have a large spectrum of activity and low propensity to induce bacteria resistance. Nonetheless, their in vivo performance may be affected as they tend to self-aggregate and undergo enzymatic degradation, which often leads to toxicity issues, and high concentrations are then required to solve these. The key this dilemma may dwell in their immobilization on biomaterials.
Over the last few decades, biomedical research has largely benefited from advances in nanotechnology. A broad range of nanomaterials, besides those functionalized with AMPs (e.g., micelles, liposomes nanocomposites, and nanoemulsions), have excellent antimicrobial properties, providing more benefits than traditional antibiotics do in terms of countering the microbial resistance mechanisms. Additionally, nanomaterials have remarkable features for targeted drug-delivery.
Altogether, this bioengineered approach may allow researchers to simultaneously tackle antimicrobial resistance and enhance the performance of conventional drugs.
Authors are kindly invited to submit original papers, communications, and reviews regarding the potential of Antimicrobial Peptides and Antimicrobial Nanomaterials to be published in this Special Issue of Pharmaceutics.
Dr. Paula Parreira
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
